posted
Advanced Cell Technology Enters Into Letter of Intent to Acquire Mytogen, Inc. and Proceed with the Human Clinical Trials Utilizing Myoblasts for the Treatment of Heart Failure
May 31, 2007 12:34:23 (ET)
ALAMEDA, Calif., May 31, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) today announced that it has entered into a letter of intent to acquire Mytogen, Inc. and its Myoblast Program for the treatment of heart failure. The letter of intent provides for an aggregate purchase price of $5 million payable in ACTC common stock plus the assumption of certain Mytogen liabilities of approximately $1 million. Mytogen will also receive a warrant to purchase an additional 1.5 million shares of ACTC common stock at $1.00 subject to achievement of certain milestones. The letter of intent is subject to several closing conditions including requisite approvals from the Food and Drug Administration (FDA), final intellectual property due diligence and execution of a definitive agreement. The transaction is scheduled to close by July 15, 2007. Upon completion of the acquisition, Advanced Cell Technology will transition from a development stage to a clinical stage company. Mytogen brings to the Company over ten years of experience in clinical trial and FDA experience in developing and advancing cellular therapies including the area of stem cells.
In regard to the Myoblast Program, Mytogen has completed successful Phase I Human Clinical Trials utilizing the therapy safely in over forty patients. The FDA has reviewed the "end-of-Phase I" data and allowed Mytogen to proceed with a Phase II Human Clinical Trial. Upon the close of the acquisition, Advanced Cell Technology plans to commence the Phase II Human Clinical Trial for the treatment of heart failure in approximately 160 patients. If successful, the Company expects to proceed with a pivotal Phase III Trial for the therapy.
The Myoblast Program may prove particularly beneficial for patients who have experienced a serious heart attack and have a high risk of heart failure. The stem cell therapy involves transplantation of expanded autologous Myoblasts (adult progenitor stem cells) derived from a small biopsy of skeletal muscle from a patient's leg. The Mytogen technology allows expansion of Myoblasts into hundreds of millions of cells over a period of two to three weeks. The resulting Myoblasts are then transplanted back into the patient's scarred heart tissue through the use of a catheter-based procedure. While the Phase I Human Clinical Trials were focused on the safety of the therapy, the clinical data from those trials suggests that the Myoblasts persist, often improve function in the heart and can lead to a significant increase in quality of life for the patient.
Advanced Cell Technology is interested in the Myoblast Program because of its potential to treat heart attack and heart failure. This is an area of significant focus for Company because of its Hemangioblast program. The catheter-based procedure of the Myoblast Program is similar to procedures that ACTC anticipates using with its Hemangioblast cell therapy. Advanced Cell Technology believes the combination of the Myoblast Program's target indication of heart failure, the catheter method of administration, and the stage of its human clinical trials, will likely generate significant findings and expertise relevant to the Company's Hemangioblast Program. The Company believes that the "here and now" of the autologuous adult stem cell therapy enables the treatment of patients today and importantly will also help deliver on the "promise of tomorrow" of human embryonic stem cell therapies.
Dr. Pedro Huertas, Chief Development Officer of Advanced Cell Technology remarked, "Mytogen has a very experienced team and is the only company that has successfully brought its technology into clinical trials in accordance with FDA regulations. The Myoblast Program takes us directly into Phase II clinical trials and is thoroughly aligned with various applications of our Hemangioblast Program."
William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology remarked, "We remain fully committed to the field of human embryonic stem cells and we believe that the promise of the Myoblast Program combined with the synergies with our Hemangioblast program provides a diverse technology platform in stem cell therapy focused on the treatment of heart attack and heart failure. We are excited to welcome Dr. Jonathan Dinsmore and the entire Mytogen team who have been together for over ten years to Advanced Cell Technology and look forward to the continued success of the Myoblast Program. We look forward to closing the transaction with Mytogen as quickly as practicable and integrating their technology and scientific team within our organization."
Additional details regarding the letter of intent with Mytogen will be included in a Current Report on Form 8-K to be filed by the Company with the Securities and Exchange Commission.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
Mytogen, Inc. is a Massachusetts based company developing autologous myoblast transplantation designed to restore cardiac function in patients with heart failure. The incidence and progressive nature of heart disease make it the leading cause of morbidity and mortality in the U. S. Mytogen is advancing a proprietary formulation of cultured human myoblasts and an optimized delivery system to deliver cells to the site of cardiac damage. Mytogen represents the consolidation of experts in areas including clinical manufacturing of biologics, cell transplantation, and stem cell biology and benefits from intellectual property assets and clinical trial experience acquired from Genvec and Diacrin, Inc. Currently, Mytogen is conducting U.S. human clinical trials of its myoblast therapy with FDA oversight, and is positioned to launch multi-center phase II studies in the near future.
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended March 31, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara or Joseph Kessler, 212-825-3210 or Media: Bill Douglass, 212-825-3210
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
posted
Related Quotes Sym. Price Chg. ACTC Trade News 0.66 0 Advanced Cell Technology to Host Conference Call and Webcast to Discuss Recent Developments and Planned Acquisition of Mytogen
Jun 4, 2007 12:40:30 (ET)
ALAMEDA, Calif, Jun 04, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) will host a conference call, which will be simultaneously webcast, on Thursday, June 7th, at 1:00PM ET. The purpose of the call is to discuss recent company developments. Among the topics to be discussed is the Company's entry into a Letter of Intent to purchase Mytogen, Inc. and its Myoblast Program for the treatment of heart failure, and its plans to commence Phase II human clinical trials to treat heart failure using Mytogen's Autologous Myoblast Stem Cell Therapy.
The call will be hosted by William M. Caldwell, IV, Chairman and Chief Executive Officer, and Pedro Huertas, M.D., Ph.D., Chief Development Officer.
William M. Caldwell, IV commented, "This planned acquisition, if completed, will hasten Advanced Cell's transformation from a preclinical development company to a clinical therapeutic company. Our Chief Development Officer, Dr. Pedro Huertas, and I are excited to have the opportunity to discuss this and other company developments with our investors and other interested parties, on Thursday's call."
Details of the call are below. Participants should dial in at least ten minutes prior to the call.
Thursday, June 7, 1:00PM ET ---------------------------
Live participant dial-in: Toll-free: 866-585-6398 International: 416-849-9626
A webcast of the call will be available through Advanced Cell's website, at www.advancedcell.com . The webcast will be available for replay through July 7, 2007.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company visit www.advancedcell.com
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended March 31, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara or Joseph Kessler 212-825-3210 or Media: Bill Douglass 212-825-3210
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
posted
ALAMEDA, Calif, Jun 04, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) will host a conference call, which will be simultaneously webcast, on Thursday, June 7th, at 1:00PM ET. The purpose of the call is to discuss recent company developments. JMO BUT WE MAY GET A BUMP UP HERE
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
posted
Related Quotes Sym. Price Chg. ACTC Trade News 0.65 0 Advanced Cell Technology's VP of Research & Scientific Development, Dr. Robert Lanza, to Deliver Opening Keynote Address at TERMIS NA 2007 Conference on Regenerative Medicine
Jun 13, 2007 10:35:12 (ET)
ALAMEDA, Calif., Jun 13, 2007 (BUSINESS WIRE) -- Advanced Cell Technology's (ACTC, Trade ) Vice President of Research and Scientific Development, Robert Lanza, M.D., will be delivering the opening keynote address at TERMIS NA 2007, a conference focusing on challenges in the fields of regenerative medicine. In Dr. Lanza's address, scheduled for Thursday, June 14, at 8:30 am, he will speak on the use of embryonic stem cells and the role they play in regenerative medicine.
TERMIS, or Tissue Engineering & Regenerative Medicine International Society, is a globally recognized group of scientific professionals practicing in the fields related to regenerative medicine. The conference will include more than 100 scientific presentations comprising the most comprehensive regenerative medicine event in North America.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
The Tissue Engineering & Regenerative Medicine International Society (TERMIS) brings together the international community of persons engaged or interested in the field of tissue engineering and regenerative medicine and promotes education and research within the field of tissue engineering and regenerative medicine through regular meetings, publications and other forms of communication. The Society also serves as an international forum to promote the informed discussion of challenges and therapeutic benefits of the application of tissue engineering and regenerative medicine technologies.
Most importantly, the Society is committed to bringing you closer to key professionals to support your mutual understanding of the field, accelerate your research in the field and to enable you to contribute to the ultimate care of patients in this very important way. To affect this interchange of information, the Society has endorsed the journal, Tissue Engineering, as its official publication and has negotiated a reduced subscription rate for members. In addition, the TERMIS publishes a quarterly newsletter for its members to keep them abreast of developments in the field. The TERMIS World Congress Meeting will be held every three years. In the interim years the Continental Chapters will host annual meetings to promote tissue engineering and regenerative medicine research regionally.
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ending March 31, 2007.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Media Bill Douglass, 212-825-3210 or Investors Joseph Kessler or James Carbonara, 212-825-3210
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
posted
Related Quotes Sym. Price Chg. ACTC Trade News 0.66 0.02 Advanced Cell Technology Announces Critical Advancements in Its RPE Program for the Treatment of Macular Degeneration and Other Retinal Degenerative Diseases
Jun 20, 2007 08:30:18 (ET)
ALAMEDA, Calif., Jun 20, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) today announced major advancements in the process of bringing its Retinal Pigment Epithelial (RPE) program into the clinic to treat various retinal degenerative diseases, including Age-Related Macular Degeneration (AMD). After preliminary discussions earlier this year with staff from the Office of Cellular, Tissue, and Gene Therapies within the Center for Biologics Evaluation and Research at the Food and Drug Administration (FDA), the company has contracted with a leading contract research organization in order to commence work on an extensive preclinical program. Earlier this month, MPI Research, located in Mattawan, Michigan, initiated pilot studies under Good Laboratory Practices (GLP) for Advanced Cell Technology's (ACT) ongoing RPE program.
This study is the first of several that will provide substantial safety data for an Investigational New Drug (IND) application, necessary for the initiation of a clinical trial. Due to the complex nature of stem cell derived cellular therapies, these studies are original, unique, and state-of-the-art. The protocols utilize therapeutic dosage levels of RPE cells based on recent data obtained through pharmacological dosage studies in the RCS rat, a key animal model of retinal disease. For the preliminary GLP studies, the company is utilizing RPE cells that have been differentiated from human embryonic stem cells, under current Good Manufacturing Practice (cGMP) conditions in its Worcester, Massachusetts facility. Applying appropriate controls as specified in the FDA's cGMP regulations, ACT staff was able to produce master and working cell banks of human embryonic stem cells. In working out a controlled, compliant manufacturing methodology, an unlimited amount of RPE cells can be derived by ACT for clinical use.
ACT scientists have also developed novel methodology to cryopreserve the RPE cell product, thereby overcoming various clinical issues faced by other cell therapy companies. ACT is planning for further dialogue with the FDA, as well as additional safety testing and other innovative analyses of the RPE cell product. ACT believes the commencement of these studies with all the work that lead up to them represents a significant milestone towards the program's success and future clinical trial.
Pedro Huertas, M.D., Ph.D., Chief Development Officer of Advanced Cell Technology remarked, "This is an important step for us and a tribute to the efforts of our team in translating a scientific finding into a potential therapeutic application. We expect that the GLP studies will move us closer to the successful filing of an IND and to FDA regulated clinical trials of RPE cells to treat retinal degenerative diseases."
Mr. William M. Caldwell, IV, Chairman and CEO of ACTC commented, "I am very proud to announce the extensive work to date on the RPE program for our company. We remain steadfast in our commitment to drive our therapeutic programs to the clinical stage."
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
About MPI Research
MPI Research, with headquarters in Mattawan, Michigan, is one of the worlds leading providers of comprehensive preclinical research and development services. More information on the company's services can be obtained through the website at www.mpiresearch.com .
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended March 31, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara or Joseph Kessler, 212-825-3210 or Media: Bill Douglass, 212-825-3210
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
Related Quotes Sym. Price Chg. ACTC Trade News 0.76 0.1 Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
Jun 21, 2007 09:35:48 (ET)
ALAMEDA, Calif., Jun 21, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) has successfully produced a human embryonic stem cell (hESC) line without destroying an embryo at its lab in Worcester, Massachusetts. This development was announced by Robert Lanza, M.D., V.P. of Research and Scientific Development of Advanced Cell Technology (ACT) on Tuesday at the fifth annual meeting of the International Society for Stem Cell Research (ISSCR) in Cairns, Australia.
In August 2006, ACT published a paper in Nature Magazine documenting a technique for removing a single cell (known as a blastomere) from an eight-cell human embryo, and using that cell to generate multiple hESCs without destroying the embryo.
At the ISSCR meeting, Dr. Lanza definitively announced that he and his team have now reproduced the work of removing a single cell blastomere from a human embryo with the surviving embryo cryo-preserved. Dr. Lanza noted at the meeting, "These are the first human embryonic stem cells in existence to be made without destroying an embryo."
This development comes on the heels of President Bush's veto of federal legislation which would have provided funding for embryonic stem cell research.
In an appearance yesterday on Bloomberg Television's "On the Economy," juxtaposed with the President's press conference relating to his stem cell funding veto, William M. Caldwell, IV, Chairman and CEO of ACT, commented on ACT's single cell blastomere development: "It does address the President's concern. We're very excited about this technology, and we're using it today to develop treatments for (addressing) macular degeneration."
Today Mr. Caldwell said, "The American people spoke through their representatives in Congress when federal funding legislation was passed by both houses and presented to the President. We are, of course, very disappointed with his veto yesterday. Our single cell blastomere technology directly addresses the President's ethical concerns and is available today, unlike the science projects announced by the President yesterday. Despite the veto, and particularly in light of this new advance, we call on the National Institutes of Health to reflect the will of the American people and approve funding for research applications of our single cell blastomere technology."
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended March 31, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara or Joseph Kessler, 212-825-3210 or Media: Bill Douglass, 212-825-3210
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
U.S. company says grows embryo-safe stem cells Fri Jun 22, 2007 2:21pm ET Market View ACTC (Advanced Cell Technology Inc ) Last: $0.70 Change: -0.02 (-2.78%) Revenue (ttm): $0.5M EPS: -1.46 Market Cap: $35.62M Time: 3:59pm ET
Company News: U.S. company says grows embryo-safe stem cells More Company News... Email This Article | Print This Article | Reprints [-] Text [+] By Maggie Fox, Health and Science Editor
WASHINGTON, June 22 (Reuters) - Researchers at a U.S. company trying to push the margins of stem cell research said on Friday they had grown human embryonic stem cells using a non-controversial method that did not harm the embryos.
They said they had grown several lines, or batches, of the cells using a single cell taken from an embryo, which they then froze unharmed.
"We generated three new lines," Dr. Robert Lanza of Advanced Cell Technology Inc. (ACTC.OB: Quote, Profile , Research) told Reuters.
Reuters Pictures
Editors Choice: Best pictures from the last 24 hours. View Slideshow
"These are first human embryonic cell lines in existence that didn't result from the destruction of an embryo."
Lanza gave a brief summary of the work to a meeting of the International Society for Stem Cell Research in Cairns, Australia this week. He plans to publish details in a medical journal.
ACT hopes the approach might bypass objections to human embryonic stem cell research. U.S. President George W. Bush vetoed a bill this week that would have broadened federal funding of such work.
Researchers say these cells, taken from days-old embryos, might provide a way to regenerate all sorts of tissues, blood and perhaps even organs. And studying them might help them learn how to reprogram ordinary cells. Continued...
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
Filed Pursuant to Rule 424(B)(3) Registration No. 333-140265
PROSPECTUS
ADVANCED CELL TECHNOLOGY, INC.
13,516,367* SHARES OF COMMON STOCK
*Does not include 20,397,296 previously registered shares that are covered by this Prospectus
This prospectus relates to the resale to the public by the selling security holders of up to 13,516,367 shares of our common stock, par value $.001 per share, underlying (i) convertible debentures issued in 2006 in the aggregate original principal amount of $10,981,250, convertible at a conversion price of $0.288, (ii) common stock purchase warrants issued in 2006 at an exercise price of $0.3168, (iii) common stock purchase warrants, with an exercise price of $0.3168, issued to a broker-dealer as commissions paid in connection with the private placement of the 2006 debentures and the 2006 warrants. Additionally, this prospectus also relates to the resale to the public by the selling security holders of up to 20,397,296 shares of our common stock, par value $.001 per share underlying (i) convertible debentures issued in 2005 in the aggregate principal amount of $22,276,250, convertible at a conversion price of $0.90, and (ii) common stock purchase warrants issued in 2005 at an exercise price of either $0.95 or $0.90.
The conversion price of each of the convertible debentures and the exercise price of the warrants described above is subject to anti-dilution and other customary adjustments.
This prospectus also covers the resale to the public by the selling security holders of up to 20,397,296 shares of common stock previously registered pursuant to that certain Registration Statement No. 333-129019, which was filed on October 14, 2005, originally declared effective October 28, 2005, and subsequently amended, including (i) shares of common stock underlying convertible debentures issued in 2005 and held by certain selling security holders, and (ii) shares of common stock issuable upon the exercise of common stock purchase warrants issued in 2005 and held by certain of the selling security holders.
This prospectus will act as a single combined prospectus as permitted by Rule 429 of the Securities Act of 1933, as amended. The selling security holders named herein may sell common stock from time to time in the principal market on which the stock is traded at the prevailing market price or in negotiated transactions. We will not receive any proceeds from the sales by the selling security holders, but we receive funds from the exercise of warrants held by selling security holders, if and when exercised. We will pay the expenses of registering these shares.
Our common stock is quoted on the OTC Bulletin Board under the symbol “ACTC.” On March 22, 2007, the closing bid and ask prices for one share of our common stock were $0.76 and $0.79, respectively, as reported by the OTC Bulletin Board. These over-the-counter quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not necessarily represent actual transactions.
These securities are speculative and involve a high degree of risk. You should consider carefully the “Risk Factors” beginning on Page 6 of this prospectus before making a decision to purchase our stock.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.
posted
wtg imake. I thought this would happen but not in one day. lol. end of week gapper? or more conversions to drive it lower? many were waiting for this. Bush's veto didn't help matters but twill be business as usual finding financing. getting warmer on their research as well so finding the money shouldn't be too difficult. imo
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
Related Quotes Sym. Price Chg. ACTC Trade News 0.43 0.035 Registration Statement for Equity Related to Advanced Cell Technology's September 2006 PIPE Becomes Effective
Jun 28, 2007 10:50:11 (ET)
ALAMEDA, Calif., Jun 28, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) announced that the registration statement related to new shares of common stock underlying the company's September 2006 PIPE (private investment in public equity) transaction became effective, and those shares became eligible for trading on June 27, 2007.
In September 2006, Advanced Cell Technology (ACT) raised over $10 million by selling senior secured convertible debentures in a PIPE transaction. On June 27, 2007, 13,516,367 additional shares of common stock became eligible for trading and over 21 million shares of ACTC changed hands, creating the highest volume day in company history.
"We are pleased that the conversion of the debentures issued in the September 2006 financing will eliminate debt from our balance sheet and mitigating a portion of the equity overhang presented by the September 2006 transaction," noted William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology. "While we are disappointed by the downward pressure on our stock price resulting from the availability of additional shares, our company remains committed to applying regenerative medicine to develop novel therapies for the treatment of diseases and indications with little or no alternatives such as retinal degenerative disorders and cardiovascular disease. We believe that as we continue to reach our developmental and clinical milestones, the market will recognize the value of our technology platform and the potential for the commercialization of our stem cell therapies."
Recently, ACT announced significant progress in both its retinal pigment epithelium (RPE) and hemangioblast (HG) programs for which the company plans to file investigational new drug (IND) applications in 2008. In May 2007, the company entered into a letter of intent to acquire Mytogen, Inc., an autologous adult stem cell company with a therapy for cardiovascular disease that has successfully completed Phase I clinical trials. Upon closing the Mytogen transaction, ACT plans to begin Phase II trials. In addition, last week ACT announced that it had developed the world's first human embryonic stem cell line without destroying an embryo, which could circumvent President Bush's objections to embryonic stem cell research.
For additional information about the registration statement (Form SB-2), please visit www.sec.gov .
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended March 31, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara or Joseph Kessler, 212-825-3210 or Media: Bill Douglass, 212-825-3210
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
posted
i'm sure the M&Ms are happy filling those convertibles eh? now get it back to .81 lol
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
and I was swingin. Guess it paid off to wait a lil before getting back in. Very nice. Should have had my alerts set.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
Advanced Cell Technology Applauds Inclusion of Stem Cell Provision In $152 Billion Federal Funding Measure
Jul 2, 2007 09:51:07 (ET)
ALAMEDA, Calif., Jul 02, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc.(ACTC, Trade ): On June 21, 2007, the U.S. Senate Appropriations Committee voted overwhelmingly in favor of a $152 billion Labor-HHS-Education appropriations bill. An amendment to the bill would expand federal funding for embryonic stem cell research by changing a critical date relating to the eligibility of stem cell lines. The amendment would fundamentally change current federal embryonic stem cell policy by permitting federally-funded research on stem cell lines that were derived before June 15 of this year, as opposed to the current marker of August 9, 2001. The committee noted that this moving of the date forward by almost six years will advance progress toward treatments and cures by significantly expanding the number of stem cell lines eligible for federally funded research.
Key among those lines would be upwards of twenty from Advanced Cell Technology (ACTC). These would include the Company's single cell blastomere lines, created without the destruction of embryos. This technique was documented in a major paper in Nature magazine in August 2006. Moreover, the Company recently announced additional lines using this embryo-safe technique, as discussed by ACTC's Chairman and CEO, William M. Caldwell, IV, in an interview on Bloomberg TV on June 20, juxtaposed with President Bush's press conference on related topics.
The legislation would provide more than $29 billion to fund biomedical research at the 27 Institutes and Centers that comprise the National Institutes of Health (NIH). This represents an increase of $1 billion over the fiscal year 2007 level and more than $1.2 billion over the President's most recent budget request.
Subcommittee Chairman Tom Harkin (D-IA) said, "We have written a bill that, I believe, reflects the real priorities and values of the American people. The bill provides $29 billion for life-saving biomedical research at the National Institutes of Health." In this same regard, Senate Appropriation Committee Chairman Robert C. Byrd (D-WV) noted, "The future of our nation and its ability to dominate in the global economy depends on the strength of our workforce, our ability to give our children access to an education that is second to none, and invest in our research facilities so that our doctors and scientists can continue to find cures for illnesses that affect millions of Americans every year."
William M. Caldwell IV urged the NIH to look favorably on all current grant applications utilizing the Company's single cell blastomere technology, saying, "If the NIH approves funding for human embryonic stem cell lines derived from a well-established, widely-used medical procedure, pre-implantation genetic diagnosis (PGD), the United States scientific and biotechnology community will have the opportunity to accelerate this technology platform which does not destroy the embryo, and translate the existing body of science into therapies destined for clinical trials. Over 2,500 children have been born in the past few years through PGD. They are alive and healthy, with loving parents and are a walking testament to the viability of PGD, which is the basis for our single cell blastomere technology."
Mr. Caldwell added, "Unlike a recently-announced technique for deriving embryonic stems cells in mice, this is not a science project years away from being utilized for therapeutic work. These embryonic stem cell lines we have developed are available today, here and now, and may be used immediately."
To watch Mr. Caldwell's June 20 interview on federal stem cell funding on Bloomberg Television, please visit ACTC's website at http://www.advancedcell.com
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ending March 31, 2007.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Media: Bill Douglass, 212-825-3210 or Investors: Joseph Kessler/James Carbonara, 212-825-3210
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
any left in this IMAKE? im lookin to catch a friday deal..
-------------------- If your not on the edge of ur seat, sell it! Everything posted is my opinion! Posts: 992 | From: H-town | Registered: Nov 2006
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Big Grin]](biggrin.gif)
![[Eek!]](eek.gif)
![[Cool]](cool.gif)
wtg imake. I thought this would happen but not in one day. lol. end of week gapper? or more conversions to drive it lower? many were waiting for this. Bush's veto didn't help matters but twill be business as usual finding financing. getting warmer on their research as well so finding the money shouldn't be too difficult. imo![[Razz]](tongue.gif)
![[Wink]](wink.gif)
